Diabetes Drug Discovery

Your partner through the entire diabetes research process. From discovery through regulatory approval.

iStock-146717117

Diabetes represents one of the leading causes of death and disability in the Western world. Charles River helps accelerate novel discoveries through innovative target identification and validation, complex in vitro and in vivo pharmacology models, and a strong chemistry and disease biology foundation, all of which assist in translating basic research to clinical reality.

A broad panel of relevant biomarkers provides additional information on overall metabolic status. Browse our biomarkers by therapeutic area, toxicological indication, and species.

  • Insulin
  • Glucagon
  • Leptin
  • Resistin
  • Adiponectin
  • Non-esterified fatty acids
  • Triglycerides
  • Cholesterol
  • HbA1c
  • Fructosamine
  • Custom multiplexed panels

Charles River is committed to advancing diabetes research. Access our latest scientific references and resources to learn more about our scientific contributions to this and other research areas.

We incorporate our scientific excellence, therapeutic area depth, innovative approach to drug discovery, and collaborative spirit to translate early stage projects into quality clinical candidates. We boast an enviable record of delivering over 75 development candidates and co-inventing over 320 patents in the last 17 years. Learn more about our multidisciplinary approach and integrated drug discovery research teams.

Related Resources